FASE
Número Europeu
2023-510323-30-00
NCT
NCT06525220
MCLA-158-CL03
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma
Detalhes
Destaques